Jane Huang
Known title: President, CMOCIK: 0001683913
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
Transaction History
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 10/4/2025 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,355 | $5K | 10/4/2025 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 7/4/2025 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,355 | $3K | 7/4/2025 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 4/4/2025 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,355 | $2K | 4/4/2025 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 1/4/2025 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,859 | $5K | 1/4/2025 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 10/4/2024 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,349 | $7K | 10/4/2024 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 7/4/2024 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,347 | $12K | 7/4/2024 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 4/4/2024 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,347 | $16K | 4/4/2024 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 1/4/2024 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,844 | $14K | 1/4/2024 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 10/4/2023 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 9,375 | — | 7/4/2023 | View on chart |
| PRLD | ▼ Sell | Tax Withholding | 3,242 | $15K | 7/4/2023 | View on chart |
| PRLD | ▼ Sell | Open Market | 13,280 | $81K | 4/6/2023 | View on chart |
| PRLD | ▲ Buy | Option Exercise | 37,500 | — | 4/4/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 500 | $139K | 12/14/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $28K | 12/14/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $28K | 12/14/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 200 | $56K | 12/14/2021 | View on chart |
| ONC | ▲ Buy | Option Exercise | 1,500 | $180K | 12/14/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 300 | $82K | 12/14/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 300 | $83K | 12/14/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 530 | $189K | 12/1/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 519 | $188K | 12/1/2021 | View on chart |
| ONC | ▲ Buy | Grant | 14,820 | $0 | 11/30/2021 | View on chart |
| ONC | ▲ Buy | Grant | 1,049 | $0 | 11/30/2021 | View on chart |
| ONC | ▲ Buy | Option Exercise | 1,500 | $180K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $38K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $38K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 300 | $116K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 300 | $113K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $38K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $38K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 200 | $76K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 200 | $75K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $39K | 11/17/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 200 | $72K | 10/19/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $37K | 10/19/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $37K | 10/19/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $38K | 10/19/2021 | View on chart |
| ONC | ▲ Buy | Option Exercise | 1,500 | $180K | 10/19/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 400 | $150K | 10/19/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 200 | $75K | 10/19/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 400 | $150K | 10/19/2021 | View on chart |
| ONC | ▲ Buy | Option Exercise | 6,000 | $720K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 400 | $160K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 150 | $61K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $41K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 790 | $315K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $41K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 913 | $361K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 700 | $277K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 700 | $278K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 200 | $81K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 400 | $160K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 583 | $234K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 536 | $210K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 328 | $129K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $39K | 9/20/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 900 | $325K | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 1,581 | $574K | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 1,800 | $648K | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 1,400 | $499K | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 1,700 | $611K | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 1 | $363 | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 4,219 | $1.5M | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 1,300 | $465K | 9/13/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 545 | $178K | 9/2/2021 | View on chart |
| ONC | ▲ Buy | Grant | 545 | $0 | 9/1/2021 | View on chart |
| ONC | ▲ Buy | Grant | 7,124 | $0 | 9/1/2021 | View on chart |
| ONC | ▼ Sell | Open Market | 542 | $168K | 9/1/2021 | View on chart |
| ONC | ▲ Buy | Grant | 542 | $0 | 8/31/2021 | View on chart |
| ONC | ▲ Buy | Grant | 7,163 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly
Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.